hrs4r
 I want to donate
Firma
SONIA DEL BARCO-BERRON
Position
Investigadors/es Col·laboradors/es
Collaborators

Publicacions

Gately L, Mesía C, Sepúlveda JM, Del Barco S, Pineda E, Gironés R, Fuster J, Hong W, Dumas M, Gill S, Navarro LM, Herrero A, Dowling A, de Las Peñas R, Vaz MA, Alonso M, Lwin Z, Harrup R, Peralta S, Long A, Perez-Segura P, Ahern E, Garate CO, Wong M, Campbell R, Cuff K, Jennens R, Gallego O, Underhill C, Martinez-Garcia M, Covela M, Cooper A, Brown S, Rosenthal M, Torres J, Collins IM, Gibbs P, Balana C

Correction to: A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma.

JOURNAL OF NEURO-ONCOLOGY, 2024, 166, 417-418 dx.doi.org/10.1007/s11060-024-04581-x
Martínez-Bosch N, Vilariño N, Alameda F, Mojal S, Arumí-Uria M, Carrato C, Aldecoa I, Ribalta T, Vidal N, Bellosillo B, Menéndez S, Del Barco S, Gallego O, Pineda E, López-Martos R, Hernández A, Mesia C, Esteve-Codina A, de la Iglesia N, Balañá C, Martínez-García M, Navarro P

Gal-1 Expression Analysis in the GLIOCAT Multicenter Study: Role as a Prognostic Factor and an Immune-Suppressive Biomarker.

Cells, 2023, 12 dx.doi.org/10.3390/cells12060843
Segura PP, Quintela NV, García MM, Del Barco Berrón S, Sarrió RG, Gómez JG, Castaño AG, Martín LMN, Rubio OG, Losada EP

SEOM-GEINO clinical guidelines for high-grade gliomas of adulthood (2022).

CLINICAL & TRANSLATIONAL ONCOLOGY, 2023, 25, 2634-2646 dx.doi.org/10.1007/s12094-023-03245-y
Gately L, Mesía C, Sepúlveda JM, Del Barco S, Pineda E, Gironés R, Fuster J, Hong W, Dumas M, Gill S, Navarro LM, Herrero A, Dowling A, de Las Peñas R, Vaz MA, Alonso M, Lwin Z, Harrup R, Peralta S, Long A, Perez-Segura P, Ahern E, Garate CO, Wong M, Campbell R, Cuff K, Jennens R, Gallego O, Underhill C, Martinez-Garcia M, Covela M, Cooper A, Brown S, Rosenthal M, Torres J, Collins IM, Gibbs P, Balana C

A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma.

JOURNAL OF NEURO-ONCOLOGY, 2023, 166, 407-415 dx.doi.org/10.1007/s11060-023-04513-1
Martínez-García M, Servitja Tormo S, Vilariño Quintela N, Arance Fernández A, Berrocal Jaime A, Cantos Sánchez de Ibargüen B, Del Barco Berrón S, García Campelo R, Gironés Sarrió R, Manuel Sepúlveda-Sánchez J

SEOM-GEINO clinical guideline of systemic therapy and management of brain central nervous system metastases (2021)

CLINICAL & TRANSLATIONAL ONCOLOGY, 2022, 24, 703-711 dx.doi.org/10.1007/s12094-022-02803-0
Hernandez A, Muñoz-Mármol AM, Esteve-Codina A, Alameda F, Carrato C, Pineda E, Arpí-Lluciá O, Martinez-García M, Mallo M, Gut M, Del Barco S, Gallego O, Dabad M, Mesia C, Bellosillo B, Domenech M, Vidal N, Aldecoa I, de la Iglesia N, Balana C

In silico validation of RNA-Seq results can identify gene fusions with oncogenic potential in glioblastoma

SCIENTIFIC REPORTS, 2022, 12, 14439-14439 dx.doi.org/10.1038/s41598-022-18608-8
Torregrosa-Maicas MD, Del Barco-Berrón S, Cotes-Sanchís A, Lema-Roso L, Servitja-Tormo S, Gironés-Sarrió R

Expert consensus to optimize the treatment of elderly patients with luminal metastatic breast cancer

CLINICAL & TRANSLATIONAL ONCOLOGY, 2022, 24, 1033-1046 dx.doi.org/10.1007/s12094-021-02766-8
Esteve-Codina A, Alameda F, Carrato C, Pineda E, Arpí O, Martinez Garcia M, Mallo M, Gut M, Dabad M, Tortosa A, Del Barco S, Capellades J, Puig J, Gallego O, Pujol T, Oleaga L, Gil-Gil MJ, de Quintana-Schmidt C, Valduvieco I, Martinez-Cardus A, Bellosillo B, Muñoz-Mármol AM, Esteve A, Domenech M, Camins A, Craven-Bartle J, Villa S, Marruecos J, Domenech S, de la Iglesia N, Balana C

RNA sequencing and Immunohistochemistry Reveal ZFN7 as a Stronger Marker of Survival than Molecular Subtypes in G-CIMP-negative Glioblastoma

CLINICAL CANCER RESEARCH, 2021, 27, 645-655 dx.doi.org/10.1158/1078-0432.CCR-20-2141
Luque R, Benavides M, Del Barco S, Egaña L, García-Gómez J, Martínez-García M, Pérez-Segura P, Pineda E, Sepúlveda JM, Vieito M

SEOM clinical guideline for management of adult medulloblastoma (2020)

CLINICAL & TRANSLATIONAL ONCOLOGY, 2021, 23, 940-947 dx.doi.org/10.1007/s12094-021-02581-1
Carrato C, Alameda F, Esteve-Codina A, Pineda E, Arpí O, Martinez Garcia M, Mallo M, Gut M, Lopez-Martos R, Del Barco S, Ribalta T, Capellades J, Puig J, Gallego O, Mesia C, Muñoz-Mármol AM, Archilla I, Arumí M, Blanc JM, Bellosillo B, Menéndez S, Esteve A, Bague S, Hernandez A, Craven-Bartle J, Fuentes R, Vidal N, Aldecoa I, de la Iglesia N, Balana C

Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy

CLINICAL CANCER RESEARCH, 2020, 26, 6600-6609 dx.doi.org/10.1158/1078-0432.CCR-20-2171

Formulari de contacte

About IDIBGI!

menu